Abstracts tagged "Vasculitis"

Abstract Number: 2491 • ACR Convergence 2023
Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort
Stefan Krämer¹, Thomas Rauen¹, Kristian Vogt¹, Teresa Anslinger¹, Martin Busch², Tobias Schmitt³, Raoul Bergner⁴, Sebastian Mosberger⁴ and Thomas Neumann⁵, ¹RWTH, University Hospital Aachen, Department of Nephrology and Rheumatology, Aachen, Germany, ²University Hospital Jena, Friedrich-Schiller University, Department of Internal Mediciine III, Jena, Germany, ³University Hospital Jena, Friedrich Schiller University, Department of Nephrology, Jena, Germany, ⁴Municipal Hospital Ludwigshafen, Department of Internal Medicine A, Nephrology and Rheumatology, Ludwigshafen, Germany, ⁵Cantonal Hospital St. Gallen, Department of Rheumatology, St. Gallen, Switzerland
Background/Purpose: In 2022, ACR and EULAR proposed new classification criteria for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) based on a numerical item scoring…
Abstract Number: 0688 • ACR Convergence 2023
Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
Federico Alberici¹, Carlo Salvarani², Christine Chan³, Achim Obergfell⁴ and Tamara Popov⁴, ¹Universita degli Studi di Brescia, Brescia, Italy, ²Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³CSL Vifor, Redwood City, CA, ⁴CSL Vifor, Glattbrugg, Switzerland
Background/Purpose: Avacopan, a selective C5aR1 inhibitor, has demonstrated efficacy and safety over 52 weeks in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. However, efficacy and…
Abstract Number: 0709 • ACR Convergence 2023
Survival of Adults with IgA Vasculitis
Alojzija Hocevar¹, JAKA OSTROVRŠNIK², vESNA JURČIĆ³, Matija Tomšič⁴ and Ziga Rotar⁵, ¹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ²UKC Ljubljana, Ljubljana, Slovenia, ³University of Ljubljana, Medical Faculty, Institute of Pathology, Ljubljana, Slovenia, ⁴Department of Rheumatology, University Medical Centre LJubljana, Ljubljana, Slovenia, ⁵University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Data on survival of adults with IgA vasculitis (IgAV) are scarce. The aim of our study was to estimate for the first time the…
Abstract Number: 1248 • ACR Convergence 2023
Thrombotic Manifestations in Pediatric Behçet Disease Patients: A Multicentre Comparative Study from EUROFEVER Registry
Maria Vincenza Mastrolia¹, Caterina Matucci-Cerinic², Seza Ozen³, Ozgur Kasapcopur⁴, Carla Gaggiano⁵, Isabelle Kone-Paut⁶, Luca Cantarini⁵, Perrine Dusser⁷, Ümmüşen Kaya-Akça⁸, Mehmet Yildiz⁹, Juergen Brunner¹⁰, Giovanni Filocamo¹¹, Romina Gallizzi¹², Antonella Insalaco¹³, Serena Pastore¹⁴, Donato Rigante¹⁵, Judith Sanchez-Manubens¹⁶, Elena Tsitsami¹⁷, Marco Gattorno¹⁸ and Gabriele Simonini¹⁹, ¹NEUROFARBA Department, University of Florence, Florence, Italy, ²DINOGMI, University of Genoa; IRCCS Istituto Giannina Gaslini, UOC Rheumatology and autoinflammatory diseases, Genova, Italy, ³Hacettepe University Medical Faculty, Ankara, Turkey, ⁴Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, ⁶Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ⁷Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ⁸Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Instanbul, Turkey, ¹⁰Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹¹Pediatric Immunorheumatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, MIlan, Italy, ¹²Department of Medical of Health Sciences, Magna Graecia University, Catanzaro, Italy, ¹³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ¹⁴Institute for Maternal and Child Health, RCCS “Burlo Garofolo", Trieste, Italy, ¹⁵Department of Life Sciences and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, ¹⁶Pediatric Rheumatology, Section Pediatric Service, Parc Taulí Sabadell University Hospital, Institute for Research and Innovation I3PT, Sant Joan de Deu Hospital, Autonomous University of Barcelona, Barcelona, Spain, ¹⁷Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, ¹⁸UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ¹⁹Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: Arterial and venous thrombosis occurs in 6.6 to 38.4% of pediatric Behçet disease (BD) and cerebral sinus is one of the most involved districts.…
Abstract Number: 1565 • ACR Convergence 2023
Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴ and David Kane⁵, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: It has been reported that up to a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It is currently…
Abstract Number: 1941 • ACR Convergence 2023
Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations
Eduardo Martin-Nares¹, Beatriz E. Sánchez-Hernández², Peter Grayson³, Jose Crispin¹, Daniel Montante-Montes de Oca², Andrea Hinojosa-Azaola¹, Gabriela Hernandez-Molina¹, Elia Apodaca⁴, Emma M. Groarke⁵, Jesús Delgado-de la Mora², Silvia Méndez-Flores⁶, Armando Gamboa-Domínguez², Bhavisha Patel⁷ and Marcela Ferrada⁸, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁴Department of Oncology and Hematology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD, ⁶Department of Dermatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷National Institutes of Health, Beltsville, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited information on VEXAS syndrome in the Latin-American population. We aimed to identify UBA1 mutations causing VEXAS syndrome in Mexican patients presenting…
Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 2492 • ACR Convergence 2023
The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life
Rula Hajj-Ali¹, Chao Zhang², Renee Borchin³, Jenn Gordon⁴, David Cuthbertson³, Carol McAlear⁵, Christine Yeung⁵, David Badenoch⁶, Cristina Burroughs³ and Peter Merkel⁵, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³University of South Florida, Tampa, FL, ⁴Vasculitis Patient Powered Research Network (VPPRN), Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Vasculitis Patient Powered Research Network (VPPRN), Los Angeles, CA
Background/Purpose: Neurologic involvement (NI) is a common manifestation in patients with ANCA-associated vasculitis (AAV) and can lead to chronic pain and disability. This project assessed…
Abstract Number: 0690 • ACR Convergence 2023
Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy
Dario Roccatello¹, Savino Sciascia², SILVIA GRAZIETTA FODDAI³, gIACOMO QUATTROCCHIO⁴, MASSIMO RADIN³, IRENE CECCHI³, ALICE BARINOTTI³, ELENA RUBINI³, MICHELA FERRO⁴, EMANUELE DE SIMONE⁴, carla naretto⁴, ANTONELLA BARRECA⁵, ANDREA SAMMARTINO⁴, DANIELA ROSSI⁴ and ROBERTA FENOGLIO⁴, ¹University of Torino, Torino, Italy, ²University of Turin, Torino, Italy, ³University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ⁴University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, ⁵Pathology Unit, Città della Salute e della Scienza, Turin, Italy
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in…
Abstract Number: 0710 • ACR Convergence 2023
The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review
Hila Ghersin¹, Michelle Toker², Urmi Khanna², Rachel Schwartz¹, Benedict Wu³ and Anand Kumthekar², ¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, ³Montefiore Medical Center, Bronx, NY
Background/Purpose: IgA vasculitis (IgAV) is associated with malignancy in adult patients [1,2]. The clinical characteristics, temporal relationship, and underlying mechanisms of malignancy-associated IgAV are not…
Abstract Number: 1250 • ACR Convergence 2023
Local Inflammatory Response Mediated by the Homing of Tfh17 Cells Is Involved in Tissue Injury of Immunoglobulin a Vasculitis
Xiaoxue Ma, Qinglian Jiang and Xuyang Chi, The First Hospital of China Medical University, Shenyang, China
Background/Purpose: Immunoglobulin A vasculitis (IgAV), also named Henoch–Schönlein purpura, is a systemic vasculitis characterized by the deposition of IgA1-dominant immune complexes in small vessels that…
Abstract Number: 1567 • ACR Convergence 2023
Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis
Tanaz Kermani¹, SEMA KAYMAZ-TAHRA², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Antoine G Sreih¹², Kenneth Warrington¹³, fatma Alibaz-Öner¹⁴, Haner Direskeneli¹⁵ and Peter Merkel⁷, ¹Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Bristol Myers Squibb, Princeton Pike, NJ, ¹³Mayo Clinic, Rochester, MN, ¹⁴Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ¹⁵Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
Background/Purpose: Damage is the irreversible consequence of disease or its treatment. This study aimed to evaluate the accrual of damage in Takayasu's arteritis (TAK) using…
Abstract Number: 2051 • ACR Convergence 2023
Screening Multisystem Inflammatory Syndrome in Children: Accuracy of SickKids Screening Pathway Compared to ACR Algorithm
Greta Mastrangelo¹, Paul Tsoukas¹, Trent Mizzi², Beth Gamulka³, Amy Xu¹, Arthur Hoi Hin Cheng¹ and Rae Yeung⁴, ¹Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Department of Emergency Medicine, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C), also known as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS), is one of the most serious…
Abstract Number: 2407 • ACR Convergence 2023
Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Chenyao Wang², Ryu Watanabe³, Hui Zhang³, Mitsuhiro Akiyama³, Kenneth Warrington⁴, Gerald J. Berry³, Jorg Goronzy⁴ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Stanford University School of Medicine, Stanford, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Giant cell arteritis (GCA) is a medium and large vessel vasculitis with pathognomonic granulomatous infiltrates in the vessel wall. During the early stages of…
Abstract Number: 2495 • ACR Convergence 2023
Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis
Natalie Atallah¹, Vahe Panossian², Xiaoqing Fu¹, Claire Cook¹ and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²American University of Beirut, Beirut, Lebanon, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].